Cure8

Why This Matters

If you have IBD, J&J’s ICOTYDE/TREMFYA‑class program could expand oral IL‑23 treatment options for ulcerative colitis and Crohn’s disease and may have implications for perianal fistulizing Crohn’s disease — an area with limited approved therapies.

Who Should Pay Attention

Patients with ulcerative colitis or Crohn’s disease (including those with perianal fistulizing disease), clinicians who treat IBD, researchers following IL‑23 therapies, and people tracking pharmaceutical pipeline news.

Study Snapshot

Story typeBusiness news
Evidence typeMarket or Business News
Source depthFull source text

What To Know

Johnson & Johnson’s earnings-call summary reports that J&J is running Phase III studies of its oral IL‑23 inhibitor (ICOTYDE/TREMFYA context) in ulcerative colitis and Crohn’s disease and highlighted recent perianal fistulizing Crohn’s disease data from a FUZION study.

The item is a commercial/earnings coverage piece summarizing company pipeline updates rather than a clinical study report.

Keep In Mind

This article is an earnings‑call/market summary, not a clinical trial report or peer‑reviewed paper. Statements reflect company commentary and analyst discussion; timelines and outcomes are prospective and may change.

Source Details

Review the original publication for the complete reporting, methods, and context.

Read Original Source
Publicationallsci.com
AuthorsAlex Lyte
Indexed viaGoogle News
Source typeWeb article
PublishedJul 20, 2026, 3:54 PM
Content availableFull source text

This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.

Related Reading

Browse latest news →